Market Access Aquipta recommended by NICE for acute migraine treatment PharmaTimesGuidance paves the way for NHS access for eligible adults in England and WalesNeuroscienceRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) PharmaTimes Guidance paves the way for NHS access for eligible adults in England and Wales Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly wins new FDA approval for eczema drug EbglyssNext: Beren pockets $300m to take Niemann-Pick disease therapy to market Related Stories Market Access pharminent June 12, 2026 Market Access AbbVie’s migraine drug cleared for migraine attacks on NHS pharminent June 10, 2026 Market Access Medicare Advantage in 2026: Enrollment Update and Key Trends pharminent June 5, 2026
